Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study of Concurrent Enzalutamide and Crizotinib.
CONCLUSIONS: Concurrent administration of enzalutamide and crizotinib resulted in a clinically significant 74% decrease in systemic crizotinib exposure. Further investigation of this combination in CRPC is not planned. Our results highlight the importance of evaluating pharmacokinetic interactions when evaluating novel combination strategies in CRPC.
PMID: 32943461 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tripathi A, Supko JG, Gray KP, Melnick Z, Regan MM, Taplin ME, Choudhury AD, Pomerantz MM, Bellmunt J, Yu C, Sun Z, Srinivas S, Kantoff PW, Sweeney CJ, Harshman LC Tags: Clin Cancer Res Source Type: research
More News: Arrhythmia | Cancer | Cancer & Oncology | Constipation | History of Medicine | Hypertension | Prostate Cancer | Pulmonary Thromboembolism | Study | Toxicology | Ventricular Arrhythmia